Exploring Bispecific Nanobodies: The Future Hope for Cancer Therapy
Recently, Ivonescimab Injection, independently developed by Akeso-Sino Biopharmaceutical Co., Ltd. and the world's first of its kind, has been officially approved for marketing. Combined with chemotherapy, Ivonescimab Injection is expected to provide a brand-new and highly effective immunotherapeutic regimen for patients with locally advanced or metastatic non-squamous non-small cell lung cancer.
Read More...